Understand and communicate with the investigator, comply with the requirements of the study and give a written, signed and dated informed consent
Male or non-pregnant, non-lactating female patients at least 18 years of age
Diagnosis of moderate to severe Ankylosing Spondylitis (AS) with prior documented radiologic evidence fulfilling the Modified New York criteria for AS
Active AS assessed by total Bath Ankylosing Spondylitis Disease Activity index (BASDAI) = 4 (0-10) at baseline
Spinal pain as measured by BASDAI question #2 = 4 cm (0-10 cm) at baseline
Total back pain as measured by visual analog scale (VAS) = 40 mm (0-100 mm) at baseline
Patients should have been on non-steroidal anti-inflammatory drugs (NSAIDs) at the maximum tolerated dose for at least 4 weeks prior to their Baseline Visit, with an inadequate response or for less than 4 weeks if withdrawn for intolerance, toxicity or contraindications
Stable dose of NSAIDs including Cyclooxygenase-1 (COX-1) or Cyclooxygenase-2 (COX-2) inhibitors for at least 2 weeks before their Baseline Visit
Patients who have been on a tumor necrosis factor alpha (TNFa) inhibitor (not more than one) must have experienced an inadequate response to previous or current treatment given at an approved dose for at least 3 months prior to baseline or had been intolerant upon administration of an anti-TNFa agent
Total ankylosis of the spine
Use of other investigational drugs within 5 half-lives of enrollment, or within 4 weeks before the Baseline Visit, whichever is longer.
History of hypersensitivity to any of the study drugs or its excipients or to drugs of similar chemical classes.
Chest x-ray, computerized tomography (CT) scan, or chest magnetic resonance imaging (MRI) with evidence of ongoing infectious or malignant process, obtained within 3 months prior to screening and evaluated by a qualified physician.
Previous exposure to secukinumab or any other biologic drug directly targeting Interleukin-17 (IL-17), Interleukin-12/23 (IL-12/23), or the IL-17 receptor, or any other biologic immunomodulating agent, except those targeting TNFa
Patients who have taken more than one anti-TNFa agent
Any intramuscular or intravenous corticosteroid injection within 2 weeks before baseline
Any therapy by intra-articular injections (e.g. corticosteroid) within 4 weeks before baseline
Previous treatment with any cell-depleting therapies
Patients taking high potency opioid analgesics (e.g., methadone, hydromorphone, morphine)

NCT03350815_inc_T3
Qualifier
moderate
NCT03350815_inc_T4
Qualifier
severe
NCT03350815_inc_T5
Condition
Ankylosing Spondylitis (AS)
NCT03350815_inc_T6
Scope
moderate to severe
NCT03350815_inc_T7
Condition
radiologic evidence
NCT03350815_inc_T8
Procedure
radiologic
NCT03350815_inc_T9
Temporal
prior
NCT03350815_inc_T10
Measurement
Modified New York criteria for AS
NCT03350815_inc_T11
Value
fulfilling
NCT03350815_inc_T12
Condition
AS
NCT03350815_inc_T13
Qualifier
Active
NCT03350815_inc_T14
Measurement
total Bath Ankylosing Spondylitis Disease Activity index (BASDAI)
NCT03350815_inc_T15
Value
= 4
NCT03350815_inc_T16
Temporal
at baseline
NCT03350815_inc_T17
Condition
Spinal pain
NCT03350815_inc_T18
Measurement
BASDAI question #2
NCT03350815_inc_T19
Value
= 4 cm
NCT03350815_inc_T20
Temporal
at baseline
NCT03350815_inc_T21
Measurement
visual analog scale (VAS)
NCT03350815_inc_T22
Value
= 40 mm
NCT03350815_inc_T23
Temporal
at baseline
NCT03350815_inc_T24
Condition
Total back pain
NCT03350815_inc_T25
Drug
non-steroidal anti-inflammatory drugs (NSAIDs)
NCT03350815_inc_T26
Multiplier
maximum tolerated dose
NCT03350815_inc_T27
Temporal
for at least 4 weeks prior to their Baseline Visit
NCT03350815_inc_T28
Reference_point
their Baseline Visit
NCT03350815_inc_T29
Condition
inadequate response
NCT03350815_inc_T30
Temporal
for less than 4 weeks
NCT03350815_inc_T31
Condition
withdrawn for intolerance
NCT03350815_inc_T32
Condition
awn for intol ty or co
NCT03350815_inc_T33
Condition
contraindications
NCT03350815_inc_T34
Scope
withdrawn for intolerance, toxicity or contraindications
NCT03350815_inc_T35
Drug
ors for at ygenase-1 (COX-1) or Cyc
NCT03350815_inc_T36
Drug
Cyclooxygenase-2 (COX-2) inhibitors
NCT03350815_inc_T37
Drug
NSAIDs
NCT03350815_inc_T38
Temporal
for at least 2 weeks before their Baseline Visit
NCT03350815_inc_T39
Reference_point
their Baseline Visit
NCT03350815_inc_T40
Scope
NSAIDs including Cyclooxygenase-1 (COX-1) or Cyclooxygenase-2 (COX-2) inhibitors
NCT03350815_inc_T41
Drug
tumor necrosis factor alpha (TNFa) inhibitor
NCT03350815_inc_T42
Multiplier
not more than one
NCT03350815_inc_T43
Condition
inadequate response
NCT03350815_inc_T44
Multiplier
approved dose
NCT03350815_inc_T45
Temporal
for at least 3 months prior to baseline
NCT03350815_inc_T46
Procedure
treatment
NCT03350815_inc_T47
Temporal
current
NCT03350815_inc_T48
Temporal
previous
NCT03350815_inc_T49
Scope
previous or current
NCT03350815_inc_T50
Condition
intolerant
NCT03350815_inc_T51
Drug
anti-TNFa agent
NCT03350815_inc_T52
Scope
tumor necrosis factor alpha (TNFa) inhibitor (not more than one)
NCT03350815_inc_T53
Scope
inadequate response to previous or current treatment given at an approved dose for at least 3 months prior to baseline or had been intolerant upon administration of an anti-TNFa agent
NCT03350815_inc_T54
Condition
Total ankylosis of the spine
NCT03350815_inc_T56
Condition
hypersensitivity
NCT03350815_inc_T57
Drug
study drugs
NCT03350815_inc_T58
Drug
excipients
NCT03350815_inc_T59
Drug
drugs of similar chemical classes
NCT03350815_inc_T60
Scope
study drugs or its excipients or to drugs of similar chemical classes
NCT03350815_inc_T61
Procedure
Chest x-ray
NCT03350815_inc_T62
Procedure
computerized tomography (CT) scan
NCT03350815_inc_T63
Procedure
chest magnetic resonance imaging (MRI)
NCT03350815_inc_T64
Temporal
ongoing
NCT03350815_inc_T65
Condition
infectious
NCT03350815_inc_T66
Condition
malignant process
NCT03350815_inc_T67
Temporal
within 3 months prior to screening
NCT03350815_inc_T68
Scope
infectious or malignant process
NCT03350815_inc_T69
Scope
Chest x-ray, computerized tomography (CT) scan, or chest magnetic resonance imaging (MRI)
NCT03350815_inc_T70
Drug
secukinumab
NCT03350815_inc_T71
Drug
biologic drug
NCT03350815_inc_T72
Qualifier
other
NCT03350815_inc_T73
Drug
Interleukin-17 (IL-17)
NCT03350815_inc_T74
Condition
targeting
NCT03350815_inc_T75
Drug
Interleukin-12/23 (IL-12/23)
NCT03350815_inc_T76
Drug
IL-17 receptor
NCT03350815_inc_T77
Drug
biologic immunomodulating agent
NCT03350815_inc_T78
Negation
except
NCT03350815_inc_T79
Drug
TNFa
NCT03350815_inc_T80
Scope
Interleukin-17 (IL-17), Interleukin-12/23 (IL-12/23), or the IL-17 receptor, or any other biologic immunomodulating agent
NCT03350815_inc_T81
Scope
secukinumab or any other biologic drug
NCT03350815_inc_T82
Multiplier
more than one
NCT03350815_inc_T83
Drug
anti-TNFa agent
NCT03350815_inc_T84
Procedure
corticosteroid injection
NCT03350815_inc_T85
Qualifier
intravenous
NCT03350815_inc_T86
Qualifier
intramuscular
NCT03350815_inc_T87
Scope
intramuscular or intravenous
NCT03350815_inc_T88
Temporal
within 2 weeks before baseline
NCT03350815_inc_T89
Reference_point
baseline
NCT03350815_inc_T90
Procedure
intra-articular injections
NCT03350815_inc_T91
Drug
corticosteroid
NCT03350815_inc_T92
Temporal
within 4 weeks before baseline
NCT03350815_inc_T93
Procedure
cell-depleting therapies
NCT03350815_inc_T94
Temporal
Previous
NCT03350815_inc_T95
Drug
high potency opioid analgesics
NCT03350815_inc_T96
Drug
methadone
NCT03350815_inc_T97
Drug
hydromorphone
NCT03350815_inc_T98
Drug
morphine
NCT03350815_inc_T99
Scope
methadone, hydromorphone, morphine